On July 1, 2025, HC Wainwright & Co. analyst Emily Bodnar reiterated a "Buy" rating for NextCure (NXTC, Financial), with a maintained price target of USD 3.00. This recommendation comes as HC Wainwright & Co. continues to express confidence in the company's potential.
The maintained price target of USD 3.00 reflects no change from the previous projection, indicating that HC Wainwright & Co. sees ongoing value at the current valuation levels. It is noteworthy that the rating has remained constant at "Buy," suggesting optimism regarding the stock's performance in the foreseeable future.
NextCure (NXTC, Financial) continues to be a focal point for investors and analysts, as the reiteration by HC Wainwright & Co. highlights the company's stable positioning in the market. Stakeholders are encouraged to consider this analyst perspective when evaluating their investment strategies.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for NextCure Inc (NXTC, Financial) is $3.00 with a high estimate of $3.00 and a low estimate of $3.00. The average target implies an upside of 538.30% from the current price of $0.47. More detailed estimate data can be found on the NextCure Inc (NXTC) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, NextCure Inc's (NXTC, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
